Fziomed Launches Oxiplex Gel in the US: A Breakthrough in Spine Surgery Care

Fziomed Introduces Oxiplex Gel in the U.S. Market

November 5, 2025 — San Luis Obispo, California
In a groundbreaking move, Fziomed, Inc. has begun the commercialization of its product, Oxiplex® Gel, in the United States. This innovative, synthetic, absorbable gel is specifically designed for use in lumbar spine procedures, targeting postoperative complications such as leg pain and neurological symptoms. This is a significant milestone since Oxiplex is the first and only gel that has received FDA authorization for intraoperative use in this specific context.

Ryan Bledsoe, Fziomed’s Vice President of Marketing and Market Access, expressed pride in introducing Oxiplex to the U.S. market, emphasizing the company’s commitment to providing solutions that enhance surgical outcomes and advance healthcare practices. With this launch, spine surgeons now have a new evidence-based tool to manage an unmet clinical need in their procedures, according to Dr. Alfred L. Rhyne, an orthopedic specialist at OrthoCarolina. The impact of this product is amplified by its validation through rigorous clinical studies and a history of successful application worldwide.

What is Oxiplex Gel?

Oxiplex Gel is a clear, absorbable gel that is applied directly to nerves and adjacent tissues during surgical procedures. Its main function is to act as a temporary barrier between tissues, effectively minimizing adhesion formation post-surgery. Numerous peer-reviewed publications have highlighted its efficacy in reducing leg pain and neurological issues following lumbar spine surgeries.

Having been available internationally since 2002, Oxiplex has successfully assisted over 750,000 patients in various spine procedures, showcasing a solid track record of safety and effectiveness. The gel is designed to be user-friendly, allowing for straightforward application during surgical closure.

Commitment to Innovation in Spine Surgery

Fziomed stands as a leader in the field of preventative products for surgical adhesion, with an emphasis on innovative biomaterials since its founding in 1996. The company is on a mission to fulfill unmet medical needs across various surgical domains, including spine, tendon, nerve, abdominal, pelvic, and intrauterine procedures.

In line with its innovative ethos, Fziomed maintains a strong presence at medical conventions. They will be participating in the North American Spine Society (NASS) 40th Annual Meeting from November 14-16, 2025, in Denver, Colorado. Attendees can visit Fziomed at Booth #615 to gain insights into Oxiplex and other leading-edge solutions focused on improving surgical techniques and patient care.

Looking Ahead

Fziomed’s launch of Oxiplex Gel is anticipated to enhance the landscape of spinal surgery significantly. As they continue their mission to improve patient outcomes through advanced medical technology, healthcare professionals now have access to a reliable tool that supports their surgical practices. For further information about the company and its products, visit fziomed.com.

This advancement is not only a testament to Fziomed’s dedication but also a welcome addition to the toolkit available for spine surgeons aiming to enhance patient recovery and satisfaction post-surgery.